FDA application holder
Corcept Therapeutics Inc
The Orange Book identifies this organization as the applicant responsible for NDA 202107.
Orange Book drug · Brand (NDA)
Korlym
Mifepristone
RLDNDA 202107 Corcept Therap
Approved
Feb 17, 2012
Strengths
1
Listed patents
18
What does the FDA Orange Book show for Korlym?
Korlym contains Mifepristone and is the new drug FDA Orange Book record for NDA 202107. The application has 1 presentation with strength, dosage-form, route, status, RLD/RS, TE, patent, and exclusivity context. Current inventory and clinical labeling are not established without an application-matched source.
- FDA application
- NDA 202107
- Application holder
- Corcept Therapeutics Inc
- Product presentations
- 1
- Marketing categories
- Prescription
- Reference roles
- RLD / RS
- TE codes
- AB
- Listed patents
- 18
- Exclusivity records
- 0
New drug application identity from the Orange Book snapshot.
The listed applicant holds the FDA application; this field does not establish the product manufacturer.
Each FDA product number remains tied to its own strength, dosage form, route, and status.
Orange Book marketing categories do not establish real-time inventory or commercial availability.
RLD and RS designations are presentation-specific, not inferred from the trade name.
Therapeutic-equivalence codes apply only within the matching Orange Book product heading.
A zero means none appear in this snapshot, not that no patent rights exist.
FDA exclusivity and listed patent protection are distinct regulatory concepts.
Sourced from the official FDA Orange Book data file · snapshot refreshed
FDA product-presentation matrix
Every product number in this exact application
| Product | Strength | Dosage form / route | Marketing status | TE code | Reference role |
|---|---|---|---|---|---|
| 001 | 300MG | TABLETORAL | Prescription | AB | RLDRS |
Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.
Who is responsible for this application?
Application holder is not the same as manufacturer
Manufacturer status
Not established by the Orange Book
A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.
Regulatory interpretation
What the record means, and what it does not
FDA marketing status
1 presentation listed as prescription
RX and OTC are Orange Book marketing categories, not real-time inventory signals. Confirm current commercial availability with labeling, the application holder, or an authoritative drug listing.
Therapeutic equivalence
TE code AB across rated presentations
An AB code is an A-rating: FDA considers the product therapeutically equivalent to pharmaceutical equivalents in the same Orange Book heading and equivalence group.
Patent & exclusivity record
18 listed patent expirations and 0 exclusivity dates remain on or after Jul 26, 2026
The latest future date recorded across those files is Aug 22, 2038. Patent and FDA exclusivity operate independently, can overlap, and do not by themselves predict a generic launch date.
Same-ingredient landscape
3 other ANDAs and 1 other NDA found
3 of the related ANDA applications are not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.
Which products are meaningfully comparable?
Exact ingredient + dosage form + route cohorts
NDA 202107 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.
Tablet · Oral
Mifepristone
- Product rows
- 5
- Active applications
- 5
- Active with AB row
- 5
Why are clinical sections unavailable?
Exact application-label matching status
Exact source match queuedQueue NDA-202107
No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.
Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.
Product detail
NDA 202107
TE ABRLDRS
- Strength
- 300MG
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- Prescription
Key dates
Approval, patents, exclusivityApproval
FDA approval date of this drug product.
14 yr 8 mo ago
Today
Patent 8921348 expires
Listed method-of-use patent (U-1643) expiration.
in 2 yr 1 mo
Patent 10842801 expires
Listed method-of-use patent (U-1643) expiration.
in 6 yr 5 mo
Patent 10500216 expires
Listed method-of-use patent (U-1643) expiration.
in 6 yr 8 mo
Patent 10166242 expires
Listed method-of-use patent (U-1643) expiration.
in 9 yr 11 mo
Patent 10166243 expires
Listed method-of-use patent (U-1643) expiration.
in 9 yr 11 mo
Patent 10660904 expires
Listed method-of-use patent (U-1643) expiration.
in 9 yr 11 mo
Patent 9943526 expires
Listed method-of-use patent (U-1643) expiration.
in 9 yr 11 mo
Patent 10006924 expires
Listed method-of-use patent (U-1643) expiration.
in 10 yr 2 mo
Patent 10495650 expires
Listed method-of-use patent (U-1643) expiration.
in 10 yr 2 mo
Patent 9829495 expires
Listed method-of-use patent (U-1643) expiration.
in 10 yr 2 mo
Patent 10151763 expires
Listed method-of-use patent (U-1643) expiration.
in 10 yr 8 mo
Patent 10195214 expires
Listed method-of-use patent (U-1643) expiration.
in 11 yr 1 mo
Patent 10842800 expires
Listed method-of-use patent (U-1643) expiration.
in 11 yr 1 mo
Patent 11969435 expires
Listed method-of-use patent (U-1643) expiration.
in 11 yr 1 mo
Patent 12097210 expires
Listed method-of-use patent (U-1643) expiration.
in 11 yr 1 mo
Patent 10231983 expires
Listed method-of-use patent (U-1643) expiration.
in 12 yr 3 mo
Patent 10314850 expires
Listed method-of-use patent (U-1643) expiration.
in 12 yr 3 mo
Patent 10780097 expires
Listed method-of-use patent (U-1643) expiration.
in 12 yr 3 mo
Patent & exclusivity timeline
Protection horizonPatent expiryExclusivity endToday
Pharmaceutical detail
FDA product recordActive ingredient
MIFEPRISTONE
Strength
300MG
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
NDA 202107
Product number
001
Marketing status
Prescription
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Listed patents
Orange Book patent file| Patent | Expires | In | Type |
|---|---|---|---|
| 8921348 | in 2 yr 1 mo | U-1643 | |
| 10842801 | in 6 yr 5 mo | U-1643 | |
| 10500216 | in 6 yr 8 mo | U-1643 | |
| 10166242 | in 9 yr 11 mo | U-1643 | |
| 10166243 | in 9 yr 11 mo | U-1643 | |
| 10660904 | in 9 yr 11 mo | U-1643 | |
| 9943526 | in 9 yr 11 mo | U-1643 | |
| 10006924 | in 10 yr 2 mo | U-1643 | |
| 10495650 | in 10 yr 2 mo | U-1643 | |
| 9829495 | in 10 yr 2 mo | U-1643 | |
| 10151763 | in 10 yr 8 mo | U-1643 | |
| 10195214 | in 11 yr 1 mo | U-1643 | |
| 10842800 | in 11 yr 1 mo | U-1643 | |
| 11969435 | in 11 yr 1 mo | U-1643 | |
| 12097210 | in 11 yr 1 mo | U-1643 | |
| 10231983 | in 12 yr 3 mo | U-1643 | |
| 10314850 | in 12 yr 3 mo | U-1643 | |
| 10780097 | in 12 yr 3 mo | U-1643 |
Active-ingredient family
Brand + generics
This is a reference-listed drug (RLD), the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2000MifeprexBrand (NDA)
NDA 020687 · Danco Labs LLC
- 2025MifepristoneGeneric (ANDA)
ANDA 216616 · Evita Solutions
- 2020MifepristoneGeneric (ANDA)
ANDA 211436 · Teva Pharms USA Inc
- 2019MifepristoneGeneric (ANDA)
ANDA 091178 · Genbiopro
How to use this record responsibly
Scope, limitations, and primary sources
What to verify before making a decision
- The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
- RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
- Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
- Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
- The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.
Official FDA references
- Electronic Orange Book record
- Orange Book preface and TE-code policy
- FDA product, patent, and exclusivity data files
Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.
Korlym: frequently asked questions
Approval, therapeutic equivalence, patents, and exclusivity for this drug, from the FDA Orange Book.
Built directly from the FDA Orange Book product, patent, and exclusivity files refreshed Jul 02, 2026, 06:34 PM. Every strength of NDA 202107 is shown on this page. Interpret patents, exclusivity, availability, and therapeutic equivalence using the limitations above.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
